Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer

Lung Cancer

Volumn 32, Issue 2, 2001, Pages 117-128

  Dingemans, Anne Marie C ^a   Van Ark Otte, Jannette ^a   Span, Simone ^a   Scagliotti, Giorgio V ^b   Van Der Valk, Paul ^a   Postmus, Pieter E ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Immunohistochemistry; LRP; MRP; Proliferation

Indexed keywords

BIOCHEMICAL MARKER; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TENIPOSIDE; ABC TRANSPORTER; ACE PROTOCOL 1; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; DOXORUBICIN; ISOENZYME; KI 67 ANTIGEN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RIBONUCLEOPROTEIN; TOPOTECAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG RESISTANCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; AMINO ACID SUBSTITUTION; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; LIFE TABLE; LUNG TUMOR; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; NUCLEOTIDE SEQUENCE; POINT MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; ISOENZYMES; KI-67 ANTIGEN; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION, MISSENSE; NEOPLASM PROTEINS; PACLITAXEL; POINT MUTATION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TENIPOSIDE; TOPOTECAN; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0034744397     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00224-5     Document Type: Article

References (50)

1. New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification
2. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
3. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines
4. The multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression
5. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines
6. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung
7. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1
8. DNA topoisomerases and topoisomerase inhibitors
9. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide
10. r 170 000 isozyme of DNA topoisomerase II in human tumor cells
11. Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide
12. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform
13. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines
14. Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα
15. MDR1 gene expression in lung cancer
16. Immunohistochemically detected p53 and p-glycoprotein predict the response to chemotherapy in lung cancer
17. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
18. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung
19. r 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
20. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
21. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues
22. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma
23. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
24. Randomized study of paclitaxel-cisplatin versus cisplatinteniposide in patients with advanced non-small-cell lung cancer
25. A new proliferation associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1
26. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerases: 170- and 180 kDa isozymes
27. Analysis of M phase specific phosphorylation of DNA topoisomerase II
28. Immunochemical detection of the multidrug resistance-associated protein (MRP) in human multidrug-resistant tumor cells by monoclonal antibodies
29. Casein reduces nonspecific background staining in immunolabeling techniques
30. Use of avid in-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures
31. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
32. A simple method to attach a universal 50-bp GC clamp to PCR fragments used for mutation analysis by DGGE
33. Detection and localization of single base changes by denaturing gradient gel electrophoresis
34. Comparison of DNA topoisomerase IIα expression in small cell and non small cell carcinoma of the lung
35. lmmunohistochemical detection of DNA topoisomerase IIα P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer
36. Clinical resistance to topoisomerase-targeted drugs
37. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
38. DNA topoisomerase II mutations and resistance to anti-tumor drugs
39. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide resistant chinese hamster ovary cell line
40. Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5-8 of the p53 gene
41. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells
42. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer
43. Multidrug resistance-associated protein and p53 protein expression in non-small cell lung cancer
44. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
45. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex
46. Human DNA topoisomerase IIα: a new marker of cell proliferation in invasive breast cancer
47. Proliferation associated nuclear antigen Ki-S1 is identical with topoisomerase IIα